藥捷安康-B(02617.HK):不知悉股價及成交量異常變動原因
藥捷安康-B(02617.HK)公佈,就交易價格及成交量近期出現異常變動。經作出查詢後,董事會確認,概不知悉導致股份出現該等股價及成交量異常變動任何原因;或任何須予公佈以避免股份出現虛假市場之資料;或根據上市規則第13.09(2)條及證券及期貨條例(香港法例第571章)第XIVA部須予披露任何內幕消息。
董事會亦確認,集團之業務營運維持正常,且集團之業務營運及財務狀況並無重大變動。
連日急升的半新股藥捷安康-B(02617.HK)今早(16日)高開15%,初段曾漲63.7%,高見679.5元屢創上市高,對比今年6月23日上市價13.15元,不足三個月累飆近50.7倍。半日收報619元,升49.16%,成交327.8萬股,涉資19.21億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.